CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2021. The put-call ratio across all filers is 0.33 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $41,745,460 | -2.9% | 1,020,921 | +0.4% | 0.01% | -12.5% |
| Q1 2024 | $42,987,576 | +90.3% | 1,016,976 | +90.9% | 0.01% | +100.0% |
| Q4 2023 | $22,588,897 | +218.9% | 532,757 | +64.2% | 0.00% | +100.0% |
| Q3 2023 | $7,083,813 | -38.7% | 324,499 | -10.8% | 0.00% | 0.0% |
| Q2 2023 | $11,562,150 | +25.7% | 363,704 | -3.5% | 0.00% | 0.0% |
| Q1 2023 | $9,196,421 | -5.0% | 377,057 | +22.8% | 0.00% | 0.0% |
| Q4 2022 | $9,681,203 | +139278.1% | 306,950 | +24.9% | 0.00% | 0.0% |
| Q3 2022 | $6,946 | +159.9% | 245,797 | +143.1% | 0.00% | +100.0% |
| Q2 2022 | $2,673 | -99.9% | 101,104 | +22.9% | 0.00% | 0.0% |
| Q1 2022 | $2,880,000 | -78.9% | 82,265 | -80.5% | 0.00% | -66.7% |
| Q4 2021 | $13,671,000 | -9.1% | 421,688 | -17.3% | 0.00% | 0.0% |
| Q3 2021 | $15,038,000 | +475.7% | 509,747 | +167.9% | 0.00% | +200.0% |
| Q1 2021 | $2,612,000 | +456.9% | 190,266 | +572.1% | 0.00% | – |
| Q4 2020 | $469,000 | – | 28,309 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 65,679,781 | $2,685,646,245 | 57.02% |
| Twin Securities, Inc. | 416,657 | $17,037,105 | 13.40% |
| Sand Grove Capital Management LLP | 919,023 | $37,578,850 | 10.99% |
| Perceptive Advisors | 10,794,876 | $441,402,480 | 10.63% |
| P SCHOENFELD ASSET MANAGEMENT LP | 796,440 | $32,566,432 | 7.87% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,353,694 | $96,242,547 | 4.60% |
| Avoro Capital Advisors LLC | 7,539,547 | $308,292,077 | 4.11% |
| Melqart Asset Management (UK) Ltd | 1,099,229 | $44,947,474 | 3.72% |
| Paradigm Biocapital Advisors LP | 2,330,508 | $95,294,472 | 3.65% |
| WATER ISLAND CAPITAL LLC | 766,933 | $31,360 | 3.33% |